By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists generally agreed that BioHarvest (BHST) has shown operational progress but remains unprofitable and faces significant risks, particularly around customer acquisition costs, churn rates, and the lack of transparency in its CDMO revenue.
Risk: High customer acquisition costs and potential high churn rates in the digital marketing shift, as well as the lack of transparency in the CDMO revenue, were the most frequently cited risks.
Opportunity: The potential for growth in the hydration category and the possibility of achieving profitability in the D2C segment by 2026 were seen as significant opportunities.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Image source: The Motley Fool.
Thursday, May 14, 2026 at 8 a.m. ET
- Chief Executive Officer — Ilan Sobel
- Chief Operating Officer — Bar Dichter
- Executive Chairman — Zaki Rakib
Need a quote from a Motley Fool analyst? Email [email protected]
Ilan Sobel: Thank you. I want to thank you all for joining us on today's call. For those of you who are new to our story, BioHarvest's North Star is to discover, develop, manufacture and democratize life-changing compounds from plants that will positively impact the health and wellness of hundreds of millions of consumers and preserve the planet for generations to come. We are a leader in Botanical Synthesis, a process that utilizes our patented non-GMO platform to produce plant-derived compounds with greater potency than the plant without having to grow the plant itself. Importantly, we required the plant just once to be able to identify the cells in the plants that produce these critical phyto nutrients.
Utilizing these cells, we conduct hundreds of experiments with our technology, optimizing the environmental conditions and food that we feed the cells to be able to get the cells to mirror and magnify the levels of the phyto nutrients they produce versus the plant. We then scale the production and elicitation of these cells in industrial scale bioreactors to produce highly soluble, bioavailable and efficacious final material in a short period of time. Our technology allows us to improve nature with the power of our science and create innovative, unique and active molecules and compounds that we can produce with unique consistency, economic viability and commercial protection.
We can use these compounds in our own proprietary products or to partner with key customers, which serve high-value markets in the pharmaceutical, nutraceutical, cosmetic and fragrance and nutrition sectors. BioHarvest today operates through 2 distinct but highly complementary business units, our direct-to-consumer products division, led by our flagship VINIA nutraceutical platform, and our CDMO services division, where we partner with third parties to develop novel plant-based compounds using our proprietary Botanical Synthesis technology. These 2 businesses represent the company's dual growth engines and provide BioHarvest with multiple pathways to revenue growth and long-term shareholder value creation.
Given their different operating models, capital requirements and stages of financial maturity, we are managing the business through a 2 lens framework designed to optimize performance, capital allocation and strategic execution across both divisions. This structure reflects the way we have operated the company since late fourth quarter 2025. And beginning in 2026, our manufacturing center of excellence will be incorporated into the CDMO organization. This will further align our manufacturing capabilities under a single platform serving both our direct-to-consumer products, business and our external CDMO partners. Importantly, while both divisions are positioned as growth engines, there are at different points in their development.
We expect the D2C business to achieve profitability in 2026 while continuing to invest behind growth and customer acquisition. In parallel, we believe the CDMO business has the potential to accelerate meaningfully in 2026 and beyond, supported by continued investment in technology capabilities and commercial infrastructure to unlock its full value potential. Now turning to the fourth quarter. We are pleased to report that our fourth quarter revenues were $9.1 million, falling within our guidance range, up 25% year-over-year. This impressive result was due to a record number of sales orders that came in from our core consumer products business that generated over $3 million in sales just for the month of December 2025, a record month.
Revenues were $34.5 million for the year, up 37% from the previous year. Our gross margins were 58% for the fourth quarter, up 100 basis points compared to the same period last year, and 59% for the year, up 400 basis points compared to last year. While the ongoing conflict in the Middle East has understandably raised concern, BioHarvest's research and manufacturing operations are operating continuously without any interruptions. Recent airspace closures have affected commercial traffic, but cargo flights have gradually resumed, and we are meeting supply chain obligations and remain fully committed to meeting our product supply obligations to our partners. However, as the situation is constantly fluctuating, we, of course, continue to monitor developments closely.
Before I go deeper into defining our achievements and focus areas for 2026, I'm going to hand over to Bar to share more details on the financial performance. Over to you, Bar.
Bar Dichter: Thank you, Ilan. Good afternoon, everyone. I will provide you with a sustained view of our financial results. A full breakdown is available in our SEC filings and in the press release that crossed the wire before market closed today. Please note that all figures are in U.S. dollars unless stated otherwise. Revenues for the fourth quarter of 2025 increased 25% to $9.1 million, within management's guidance. The increase was largely due to the growth in the VINIA franchise, which exceeded 85,000 active users as of March 2026.
Gross profit increased 27% to $5.2 million or 58% of total revenues in the fourth quarter of 2025 as compared to $4.1 million or 57% of total revenue in the same year ago quarter. The increase in gross margin was primarily driven by the benefit of revenue mix, in case manufacturing scale and improved manufacturing yields. Total operating expenses for the fourth quarter totaled $6.3 million as compared to $5.8 million in the same year ago quarter. The increase in operating expenses was primarily due to an increased marketing spend and higher expenses from the CDMO service division.
Total operating expenses shrunk on a percentage of revenue to 70% as compared to 80% of revenue in the same year ago quarter. Net losses for the fourth quarter of 2025 totaled $2.2 million or $0.10 per basic and diluted share as compared to a net loss of $3 million or $0.17 per basic and diluted share for the same period last year. Adjusted EBITDA and non-IFRS measure totaled $0.5 million as compared to an adjusted EBITDA loss of $1.8 million for the same year ago quarter. Cash and cash equivalents as of December 31, 2025, totaled $23 million as compared to $2.4 million as of December 31, 2024. I would like now to pass the call back to Ilan.
Ilan Sobel: Thank you, Bar. Let's now turn to talk about the performance of our VINIA business. We continue to see strong growth in our core business, with our website, vinia.com, continuing to do the heavy lifting and delivering approximately 80% of our revenues, with over 90% of these revenues being highly valuable subscription revenue. Amazon sales, which comprised approximately 20% of our sales revenue, continued to also be a strong contributor for growth in our business.
I'm also extremely proud to announce that given the full year revenues of $30.6 million for our D2C business in the U.S.A., we have achieved the total position of being the #1 Resveratrol polyphenol brand in the United States of America based on estimated market sizing utilizing Nielsen IQ 2025 market projections for total U.S.A. for Resveratrol nutritional supplements and beverages and Amazon sales data for Resveratrol nutritional supplements. This is a major achievement for us as a company, given the fact that we have achieved this major achievement in less than 5 years from entering the U.S. market. And today, collectively with Israel, we have more than 85,000 active users of the VINIA brand.
VINIA's leadership position is driven by its clinically demonstrated ability to increase arterial dilation, improving blood flow and enabling enhanced delivery of oxygen and nutrients throughout the body. This mechanism of action addresses what many medical experts increasingly recognize as one of the most foundational elements of human health and performance, efficient blood flow and oxygen delivery. Given the recognized importance today by medical experts on arterial health and blood flow and the inimitable characteristics of our VINIA compound, we believe that we have developed a best-in-class blood flow transportation system in the body to make other synergistic nutrients work harder.
This, we are seeing as a major asset, which we will utilize in 2026 to accelerate the growth of our direct-to-consumer business. I want to turn our attention now to talk about one of our major focus areas for 2026, our VINIA BloodFlow Hydration launch, which we officially launched on December 3 to the U.S. market with a very differentiated promise of providing American consumers with electrolyte powering cells through better blood flow delivery. Let me explain for a moment how important that is. There are a myriad of electrolyte drinks that currently exist in the market today for hydration. But it's important to understand that water and electrolyte alone are not enough.
Without blood flow, the water and electrolytes have nowhere to go. VINIA significantly increases arterial dilation, enhancing blood flow and improving the delivery of fluids, electrolyzed oxygen to our body organs, tissues and trillions of cells. VINIA acts as an amazing blood flow transportation system across our 60,000 miles of arteries, veins and capillaries for any nutritional ingredients, in this case, electrolytes, to better reach the body's trillions of cells due to the ability to increase blood flow and oxygen via increased arterial dilation. We have been very encouraged by the first 16 weeks of our BloodFlow Hydration launch.
So now I'd like to share some specific facts that highlight why we believe we have a category disruptor in our hands, given its category differentiation anchored in our core strategy of delivering superior science, superior efficacy and superior taste. Since launch, our VINIA BloodFlow Hydration has achieved the following key results, which give us the confidence that we have a high-performing category disruptor in our hands, which requires further investment to realize its key potential. One, VINIA BloodFlow Hydration is now the #2 contributor to incremental new customer sales with 15% of new customer revenue year-to-date on vinia.com, ahead of all other categories except capsules.
Two, VINIA BloodFlow Hydration has achieved a verified rating of 4.8 out of 5 via vinia.com after more than 90 reviews. And three, VINIA BloodFlow Hydration has achieved a rating on Amazon of 4.9 out of 5 after approximately 50 Amazon reviews across all flavors and variety packs. This is currently one of the highest rating of any top 100 electrolyzed products on Amazon. Given these very positive early signals over the past 16 weeks and the approximate 50% premium we have been able to command versus key market leaders, we will accelerate direct marketing dollars behind VINIA BloodFlow Hydration to capture our fair share of this $17 billion category in North America.
VINIA BloodFlow Hydration plays an important role for us to be able to broaden the age demographic of our core customer base. Today, our customer base is skewed towards our super senior consumers. These are consumers who are above the age of 65. We have identified that VINIA BloodFlow Hydration is able to appeal to this consumer base, but also, importantly, has significant traction with our [ super seeker ] customer, age 35 to 65, who is looking for better longevity options to support their aging process. And more specifically, our super active consumer, who is aged 20 to 35, who are looking for a hydration solution that is more performance-based.
Accordingly, we have spent a large part of Q1 adjusting our marketing mix away from traditional TV aimed at our super senior consumer, which has been the lion's share of our marketing spend dollars in the past, and moved this to digital channels such as Facebook, Instagram, YouTube and now, we have recently opened our TikTok shop so as to more effectively recruit our important younger super seeker and super active consumer segments. This shift to digital media channels also provides us with an opportunity to improve our cost of customer acquisition versus our previous heavy reliance on TV.
We are currently utilizing Q1 to best optimize our marketing mix to deliver the step change in growth we expect in Q2, driven by scaling VINIA BloodFlow Hydration and its ability to appeal to a much broader consumer audience with the expectation to drive aggressively, new customer acquisition in Q2 at a lower cost of acquisition. I want to talk now about our second major focus area, which I termed as a big bet during our previous quarterly update in November last year and is also becoming a strategic asset for the company: our health professionals, our Health Pros channel.
This initiative, where we are acquiring critical health-driven opinion leaders with large social media followings to advocate and sell VINIA to their social media followers, is really starting to scale. The initiative has gained significant traction over the past 90 days, and we are starting to see the positive effects of scaling these opinion leaders. Right now, we have partnered with 250 Health Pros, and we will be adding approximately 25 to 50 Health Pros per month. This channel, for example, in the month of March, has delivered more than 10% of incremental new customer revenue, and we expect it to be an important contributor to future new customer revenue as this marketing channel continues to scale.
Further, this month, we kicked off a consumer challenge for our BloodFlow Hydration product on March 17, together with all our Health Pros. And as of today, more than 1,300 consumers have signed up to our 30-day BloodFlow Hydration challenge, and we are seeing amazing results across social media with consumers posting their results every day, highlighting their increase in physical activity when partnering with VINIA BloodFlow Hydration. In 2026, we will continue to leverage this powerful fact that VINIA is a best-in-class nutrient delivery system for ourselves, given its ability to significantly increase arterial dilation, improving blood flow and the delivery of targeted synergistic active ingredients to our body's organ tissues and cells.
Accordingly, our goals for this year are to leverage this insight to drive aggressive premiumization of our business by targeting relevant multibillion-dollar synergistic revenue pools in the nutraceutical industry, where we believe our blood flow delivery advantage, combined with high-performing synergistic active ingredients, will be category disruptors and will enable us to increase key financial metrics such as revenue per month and gro
Four leading AI models discuss this article
"Revenue growth and margin expansion are real, but unquantified CDMO contribution and persistent losses leave the dual-engine story unproven."
BHST reported Q4 revenue of $9.1M (+25% YoY) and full-year $34.5M (+37%), with gross margins expanding to 58-59% and cash rising to $23M. VINIA D2C now claims #1 U.S. resveratrol position, while the new BloodFlow Hydration SKU shows strong early ratings and 15% of new-customer revenue. Yet net losses persist at $2.2M, operating expenses remain 70% of revenue, and CDMO revenue is never quantified despite being labeled a second growth engine. The Middle East operating risk is acknowledged but dismissed in one paragraph. Shifting marketing from TV seniors to digital younger demographics and Health Pros is unproven at scale.
The 37% top-line growth and cash infusion could mask that D2C profitability is still only promised for 2026 and CDMO traction remains anecdotal.
"BHST has real unit economics momentum and a differentiated product, but the path to sustained profitability depends entirely on whether the digital marketing pivot and premiumization strategy work—neither is de-risked yet."
BHST shows genuine operational progress: 37% YoY revenue growth, 400bps gross margin expansion, adjusted EBITDA swing from -$1.8M to +$0.5M, and $23M cash (vs $2.4M prior year). The #1 resveratrol position claim is credible given Nielsen/Amazon data cited. BloodFlow Hydration's 4.8-4.9 ratings and 15% new customer contribution in 16 weeks suggest real product-market fit. However, the company is still unprofitable on GAAP (-$2.2M Q4), burning cash on marketing shift to digital/TikTok, and betting heavily on premiumization in a crowded wellness category. D2C profitability promised for 2026 remains unproven.
The 85,000 active users across two countries is modest for a company claiming category leadership; churn rates and LTV:CAC ratios are conspicuously absent from the transcript, and the shift away from TV (proven channel for seniors) toward TikTok for younger demos is speculative—this could crater Q2 if digital CAC doesn't compress as promised.
"BioHarvest's transition to a digital-first, multi-category model provides the necessary leverage to scale past its current niche, provided they successfully optimize CAC in the competitive hydration space."
BioHarvest (BHST) is at a critical inflection point. Achieving #1 status in the Resveratrol market with $34.5M in annual revenue is impressive, but the pivot to the $17B hydration category is the real catalyst. Moving from a 'super senior' demographic to a younger, digital-native audience via TikTok and Health Pros is a high-risk, high-reward strategy. While they achieved positive adjusted EBITDA of $0.5M this quarter, the sustainability of this hinges on whether they can lower customer acquisition costs (CAC) through digital channels. The shift from TV to social media is essential, but they are entering a brutal, saturated market where brand loyalty is fickle and margins are often eroded by heavy promotional spending.
The company’s reliance on a single core compound (VINIA) creates massive concentration risk; if the 'blood flow' efficacy claims face regulatory scrutiny or fail to resonate with the younger demographic, the entire growth thesis collapses.
"BHST’s path to value rests on durable D2C profitability by 2026 and a scalable CDMO engine, not just a promising early-stage BloodFlow launch or optimistic marketing metrics."
BioHarvest presents a two-pronged growth thesis: VINIA D2C profitability targeted for 2026 and a faster-ramping CDMO, funded by a strengthened balance sheet (cash $23M) and improving gross margins (~59%). The BloodFlow Hydration launch is positioned as a category disruptor with strong early trials and digital marketing shift, plus a Health Pros network expected to scale incremental revenue. Yet the core risks are execution and ROI: marketing spend must convert to durable CAC reductions, the BloodFlow upside hinges on sustained demand beyond early adopters, and the CDMO ramp may face competitive/commissioning headwinds. Regulatory, supply-chain, and channel concentration risks add to the uncertainty for a micro-cap like BHST.
The BloodFlow premium and Health Pros ROI may prove elusive, and profitability hinges on aggressive marketing and CDMO execution that hasn’t proven itself at scale; the upside could be much pricier than the market currently prices.
"Absent churn and LTV:CAC metrics make the 2026 D2C profitability claim unreliable."
Claude correctly flags the missing churn and LTV:CAC data, but this omission is more damaging than noted because it directly questions whether the BloodFlow 15% new-customer contribution can scale without eroding the 59% gross margins. If digital CAC fails to compress as promised, the adjusted EBITDA swing to +$0.5M could reverse quickly even with 37% revenue growth intact. The 2026 profitability target then rests on unverified assumptions rather than demonstrated unit economics.
"Adjusted EBITDA positivity is hollow without proven cohort retention and repeat purchase rates for BloodFlow."
Grok nails the unit economics trap, but I'd push harder: the 15% BloodFlow contribution to new customers is meaningless without cohort retention data. If those new users churn at 40% monthly (common for digital wellness), the $0.5M adjusted EBITDA is a mirage. The real test isn't Q1 revenue—it's whether BloodFlow repeats in Q2 without a launch halo. That data point doesn't exist yet, and management won't volunteer it if it's ugly.
"The lack of CDMO revenue quantification is a critical red flag that undermines the company's valuation as a technology platform rather than a struggling CPG brand."
Claude and Grok are hyper-focused on D2C churn, but you are all ignoring the 'CDMO' black box. If BHST is truly a technology platform, the CDMO revenue is the only way to achieve non-dilutive scale. By ignoring the lack of transparency here, you're treating this as a simple CPG company. If the CDMO pipeline doesn't materialize, the D2C unit economics won't matter because the company will be forced back to the capital markets for more cash.
"CDMO visibility is essential; calling it the sole path to non-dilutive scale is risky without transparent pricing, backlog, and customer data."
Gemini, your focus on the CDMO engine is valuable, but calling it the only route to non-dilutive scale assumes transparency will come for free. The 'CDMO black box' matters precisely because pricing, backlog, and customer mix are undefined; a slip here could cut EBITDA even if D2C improves. In short, the thesis hinges on two levers: fragile D2C unit economics and an opaque CDMO pipeline—both deserve skepticism.
The panelists generally agreed that BioHarvest (BHST) has shown operational progress but remains unprofitable and faces significant risks, particularly around customer acquisition costs, churn rates, and the lack of transparency in its CDMO revenue.
The potential for growth in the hydration category and the possibility of achieving profitability in the D2C segment by 2026 were seen as significant opportunities.
High customer acquisition costs and potential high churn rates in the digital marketing shift, as well as the lack of transparency in the CDMO revenue, were the most frequently cited risks.